



New Reimbursement Policy on Costly Treatments for Rehabilitation Care in France: Estimated Impact in a University Hospital.



EE352

<u>Legoupil T</u>¹, Tano M^{1,2,3}, Siorat V¹, Ribault M¹, Parent de Curzon O¹, Degrassat-Théas A^{1,2,3}, Paubel P^{1,2,3}

- ¹General Agency of Equipment and Health Products (AGEPS), AP-HP, Paris, France
- ²Health Law Institute, INSERM UMR S 1145, Paris Cité University, Paris, France
- ³Faculty of Pharmacy, Paris Cité University, Paris, France

Introduction Rehabilitation care (RC) funding in France is under reforming. A reimbursement policy of costly treatments will be introduced in 2023, similarly to acute care (AC): List of costly molecules for AC (LA) Administrations of these molecules (shared with AC) are fully covered by the national health insurance in addition to the Financial impact List of costly diagnosis-related group molecules specific to RC (LR)

Method Data from 39 facilities : globally + RC units only HÔPITAUX **ASSISTANCE** PUBLIQUE ' LA + LR consumption in 2021


2023

Quantity (units)

Cost (based on contracts' prices)

Results RC 4k beds available 21k full hospitalisation stays 59% of beds in (554k AC full hospitalisation stays) (21% of AP-HP) geriatric units (2021)Fig. 1. Top 5 by cost of consumption of reimbursed molecules from AC list by ATC class, of RC units of AP-HP in 2021 501 units (19%) € 1.5M, 3k units Anti-haemorrhagics 988 543 € (67%) = emicizumab, factor VIII, IX and von Willebrand 378 units (14%) Anti-neoplastics 234 969 € (16%) *=* € 4.8M Anti-diarrheals, intestinal anti-inflammatory/anti-1114 units (41%)(9,1% of AP-HP) infective agents = fidaxomicine 72 860 € (5%) 0.4% Other drugs for disorders of the musculo-skeletal 1 unit 71 367 € (5%) of total drug cost system = nusinersen **70** units (3%) of AP-HP Immune sera and immunoglobulins 36 103 € (2%) (>1,1Md€) Expenses (€) 54% Fig. 2. Top 5 by cost of consumption of reimbursed molecules from RC list, by ATC of RC's total drug class, of RC units of AP-HP in 2021 cost 1 174 066 € (35%) Muscle relaxants 201 196 (64%) (46% of AP-HP) (21% of AP-HP) = baclofene, botulinum toxin 284 537 € (9%) LR Immunosuppressants 33 019 (11%) € 3.3M, 312k units 458 287 € (14%) Anti-anemic preparations 5 032 (2%)

Conclusion



The addition of a specific RC list better encompasses chronic treatments and broadens the access to costly molecules.



12 740 (4%)

5 396 (2%)

€ 3.3M secured, which represents 37% of the total budget for medicines in RC.

Quantity (units)

284 787 € (9%)

229 770 € (7%)

Expenses (€)



National fixed reimbursement rates will be published in 2023.

Expenses are

concentrated on

few references

= darbepoetine alfa, iron

Anti-neoplastics

Anti-virals for systemic use